Retrospective study of non–small cell lung cancer(NSCLC) pts Rx w/ immune checkpoint inhibitor finds that those who develop immune-related AE (irAEs) (n=803) have improved overall survival (23.7 vs 9.8 mos survival; P < .001) https://t.co/yiwJZJU10W https://t.co/fwFFlf7Q6L
Links:
irAEs and Survival Among Patients With Metastatic NSCLC Treated With ICIs
https://bit.ly/3OGNch7
Feb-15-2024
